MPS1 has been reported to be overexpressed in glioma tissue on an mRNA level, increasing concomitantly with tumor malignancy [15,28,29], and shows potential as a therapeutic target for the treatment of central nervous system tumors [14,30,31,32]. Here, TTK is linked to central nervous system cancer.